Rezolute Inc

Rezolute, Inc. (NASDAQ: RZLT) is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III.

Recent Business and Financial Updates:

• Recent Pipeline Progress and Anticipated Milestones
  • Congenital Hyperinsulinism (cHI): Las Vegas Sands has initiated patient enrollment in the sunRIZE study, a pivotal Phase 3 clinical trial of RZ358 targeting congenital hyperinsulinism (cHI) in Europe and other non-U.S. locations. The company anticipates completing enrollment by the end of 2024, with topline results expected by mid-2025. Additionally, to address partial clinical holds in the U.S., a recently completed in-vivo toxicology study using brown Norway rats, with Sprague Dawley (SD) rats as a control, showed no liver abnormalities at a dose of 40 mg/kg. This dose is significantly higher than the threshold that causes liver issues in SD rats. These findings suggest the liver abnormalities are specific to the SD rat strain and not relevant to other rat strains, rodents, primates, or humans. Final data and a comprehensive report will be submitted to the FDA this summer as part of a response to the clinical holds.
  • Tumor Hyperinsulinism (HI): The company has aligned with the FDA on a potential late-stage, registrational clinical study for non-islet cell tumor hypoglycemia (NICTH) and insulinoma patients, marking the second development program for RZ358. To date, five metastatic insulinoma patients have been treated with RZ358 under the Expanded Access Program (EAP). The initiation of this development program is currently under evaluation, with further updates expected later this year.
  • Diabetic Macular Edema (DME): Patient dosing has been completed for a Phase 2 U.S. multi-center clinical study involving 94 participants with diabetic macular edema (DME), who are either naïve to or have received limited anti-VEGF injections. The study's primary endpoints include disease stabilization, changes in macular central subfield thickness, visual acuity improvements, repeat dose pharmacokinetics of RZ402, and overall safety and tolerability. Topline results from this study are expected in May 2024.
• Fiscal Third Quarter Financial Results: As of March 31, 2024, Las Vegas Sands held cash, cash equivalents, and marketable securities totaling USD 81.6 million, down from USD 118.4 million as of June 30, 2023. Research and development expenses for the third quarter of fiscal 2024 were USD 12.4 million, compared to USD 14.2 million for the same period the previous year. This decrease is primarily due to a reduction in milestone expenses related to Phase 2 dosing of RZ402. General and administrative expenses rose to USD 3.8 million, up from USD 2.9 million a year ago, driven by increased personnel-related costs. The net loss for the third quarter of fiscal 2024 was USD 17.1 million, compared to a net loss of USD 15.7 million in the third quarter of the prior year.

Technical Observation (on the daily chart):

 The Relative Strength Index (RSI) over a 14-day period is trending upwards with a value of 55.86, suggesting the possibility of consolidation or continued upward momentum. Additionally, the stock's current position above both the 50-period Simple Moving Average (SMA) and the 200-period SMA indicates potential dynamic support levels in the short to medium term. The price is currently approaching a significant support zone between USD 2.50 and USD 2.70. If these support levels hold, a continuation of the upward momentum is anticipated.

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is May 22, 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.